Search & Analyze

Acutaas Chemicals Ltd.

HealthcarePharmaceuticals & Drugs

www.acutaas.com BSE: 543349NSE: ACUTAAS

₹3,365.00BSE2.93%

16 Sep, 4:01 PM

₹3,365.00

₹26.76K Cr

69.30

15.51

24.08%

₹3,365.00

₹3,186.40

₹3,735.00

₹1,290.05

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	36.40	4,44,716.74	0.87	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,199.70	83.41	2,44,223.13	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,823.05	84.58	1,83,453.32	0.78	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,105.00	24.29	1,10,224.17	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,359.75	32.62	1,09,848.55	0.96	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,906.00	95.03	1,02,983.51	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,145.25	29.78	95,591.76	0.70	435.60	-69.10%	8,099.80	-5.51%	13.75
Acutaas Chemicals Ltd. ACUTAAS	3,365.00	69.30	26,764.49	0.08	74.99	70.40%	329.68	59.08%	32.42

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	176.67	246.73	274.99	308.48	207.24	306.20	393.18	432.75	329.68
Expenses	147.15	197.80	206.32	223.53	156.33	210.87	242.53	249.24	216.60
	29.52	48.93	68.67	84.96	50.91	95.32	150.66	183.51	113.07
	16.71%	19.83%	24.97%	27.54%	24.57%	31.13%	38.32%	42.41%	34.30%
	1.04	8.44	1.67	5.78	15.94	9.84	4.70	11.11	1.80
Interest	4.43	0.50	0.69	0.60	0.64	0.58	0.86	1.19	1.14
	6.18	6.83	6.32	7.30	8.13	8.40	9.83	9.63	9.82
	19.96	50.04	63.33	82.83	58.08	96.18	144.67	183.80	103.91
	26.38%	24.93%	28.25%	24.29%	24.22%	25.29%	26.58%	26.94%	27.83%
	13.94	37.33	44.95	62.48	44.29	72.24	107.96	131.76	74.26
	3.41	9.12	10.98	7.63	5.41	8.82	13.19	16.09	9.07

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	520.14	616.73	717.47	1,006.88	1,339.37
	520.14	616.73	717.47	1,006.88	1,339.37
EXPENDITURE :
Increase/Decrease in Stock	-9.50	-14.96	-28.48	-17.63	-29.00
Raw Material Consumed	282.33	345.85	440.17	569.81	594.96
Power & Fuel Cost	21.40	22.28	25.82	30.12	37.36
Employee Cost	41.37	48.84	63.11	83.66	117.57
Other Manufacturing Expenses	49.66	46.98	47.35	51.77	66.88
General and Administration Expenses	7.30	9.93	12.97	19.23	30.66
Selling and Distribution Expenses	19.92	26.49	19.88	29.63	31.31
Miscellaneous Expenses	2.49	8.71	8.15	8.22	9.23
	414.96	494.13	588.98	774.80	858.97
Operating Profit (Excl OI)	105.18	122.61	128.49	232.07	480.40
	2.76	4.32	7.49	16.93	41.59
	107.94	126.93	135.98	249.00	521.98
Interest	6.41	2.41	5.94	6.22	3.27
PBDT	101.53	124.51	130.04	242.78	518.71
	10.08	12.34	16.06	26.62	35.99
Profit Before Taxation & Exceptional Items	91.45	112.17	113.99	216.16	482.73
Exceptional Income / Expenses			-32.08
	91.45	112.17	81.90	216.16	482.73
Provision for Tax	19.50	28.88	33.19	55.75	126.36
	71.95	83.29	48.71	160.42	356.37
Extra items				0.00	0.00
Minority Interest			-5.94	-1.70	-0.11
Consolidated Net Profit	71.95	83.29	42.77	158.71	356.26
Adjustments to PAT		0.05
Profit Balance B/F	131.28	203.00	275.64	307.12	453.43
Appropriations	203.23	286.34	318.41	465.84	809.69
Equity Dividend %	30.00%	30.00%	30.00%	30.00%	50.00%
	19.75	22.86	11.60	19.39	43.51
Adjusted EPS	9.87	11.43	5.80	9.69	43.51

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	36.44	36.44	36.88	40.93	40.94
Share Warrants & Outstandings			2.31	0.11	3.11
Total Reserves	485.84	557.52	634.81	1,268.59	1,609.51
Reserve excluding Revaluation Reserve	485.84	557.52	634.81	1,268.59	1,609.51
Revaluation reserve			0.00	0.00
	522.27	593.96	674.00	1,309.63	1,653.56
Minority Interest			8.76	10.45	57.19
Secured Loans	0.59	0.63	113.64
Deferred Tax Assets / Liabilities	6.26	8.83	13.02	19.63	28.71
Other Long Term Liabilities				4.75	9.11
Long Term Provisions	0.44	0.68	1.32	2.55	4.59
Total Non-Current Liabilities	7.29	10.13	127.98	26.93	42.40
Trade Payables	118.42	142.05	134.61	156.05	153.91
Other Current Liabilities	4.88	6.64	64.78	13.48	12.44
Short Term Borrowings		2.77	72.59	8.18	26.49
Short Term Provisions	6.02	11.39	13.20	24.54	37.98
Total Current Liabilities	129.32	162.85	285.17	202.25	230.81
Total Liabilities	658.88	766.94	1,095.90	1,549.26	1,983.96
Gross Block	231.14	297.69	481.95	651.64	862.09
Less: Accumulated Depreciation	26.60	38.74	54.79	81.25	117.23
Net Block	204.53	258.95	427.16	570.39	744.86
Capital Work in Progress	1.89	25.52	125.42	130.28	332.32
Non Current Investments	1.71	1.65	0.20	0.20	0.20
Long Term Investment	1.71	1.65	0.20	0.20	0.20
Long Term Loans & Advances	14.23	17.20	48.59	55.88	24.42
Other Non Current Assets	5.87	2.21	1.23	0.88	0.91
Total Non-Current Assets	229.31	309.81	602.60	757.63	1,102.69
Inventories	112.17	119.17	156.73	179.94	231.32
Sundry Debtors	163.70	230.26	206.35	290.49	362.56
Cash and Bank	99.55	58.67	53.31	248.93	224.83
Other Current Assets	11.09	7.95	4.44	3.07	5.30
Short Term Loans and Advances	43.05	41.08	72.47	69.20	57.24
Total Current Assets	429.57	457.13	493.30	791.64	881.27
Net Current Assets (Including Current Investments)	300.25	294.28	208.13	589.39	650.46
Total Assets	658.88	766.94	1,095.90	1,549.26	1,983.96
Contingent Liabilities	2.70	2.70	2.07	15.38	17.25
Total Debt	0.84	3.60	216.65	8.18	26.49
	143.34	163.01	182.13	159.95	201.59
Adjusted Book Value	71.67	81.50	91.06	79.98	201.59

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	91.45	112.17	81.90	216.16	482.73
Adjustment	13.64	14.09	49.79	18.92	14.13
Changes In working Capital	-94.21	-36.28	17.82	-70.01	-93.11
Cash Flow after changes in Working Capital	10.88	89.98	149.52	165.08	403.74
Cash Flow from Operating Activities	-11.93	65.53	125.17	118.34	292.17
Cash Flow from Investing Activities	-120.72	-33.04	-365.39	-223.94	-265.94
Cash Flow from Financing Activitie	140.26	-12.25	239.36	261.12	4.10
Net Cash Inflow / Outflow	7.61	20.24	-0.86	155.52	30.33
Opening Cash & Cash Equivalents	2.68	10.30	30.53	29.70	185.22
Effect of Foreign Exchange Fluctuations			0.03
Closing Cash & Cash Equivalent	10.30	30.53	29.70	185.22	215.55

Ratios

Valuation

69.30

15.51

46.61

18.31

47.17

210.75

Profitability

24.08

32.42

20.17

35.87

26.61

Leverage & Liquidity

0.02

3.82

148.71

Returns

0.08

0.76

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	35.98	35.97	35.96	35.96	32.66	32.66	32.66	32.66	32.66
	27.73	33.80	35.77	34.80	39.33	39.45	38.38	39.09	41.18
	36.29	30.23	28.27	29.23	28.01	27.89	28.96	28.24	26.16
	64.02	64.03	64.04	64.04	67.34	67.34	67.34	67.34	67.34
No. of Shareholders	90,987	93,394	95,756	1,14,060	1,19,890	1,08,664	1,10,363	1,12,939	1,25,569

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-08-28	AGM
2026-07-20	Board Meeting	Quarterly Results
2026-04-30	Ex Dividend	Rs.2.5000 per share(50%)Final Dividend	2026-09-17	2026-09-17

Insider Trading

Date	Person	Category	Transaction Type	Shares
2026-06-02	Virendra Nath Mishra	Market	Sell	119
2026-06-02	Virendra Nath Mishra	Market	Sell	40,000
2026-06-02	Virendra Nath Mishra	Market	Buy	119

Sector Overview

HealthcarePharmaceuticals & Drugs

Acutaas Chemicals Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

9 members across the board and senior leadership

Ekta K Srivastava

Company Secretary & Compliance Officer

—

Nareshkumar Patel

Chairman & Managing Director

₹6.42 Cr

Mar '26

Chetankumar Vaghasia

Whole Time Director

₹6.42 Cr

Mar '26

Virendra Nath Mishra

Whole Time Director

₹1.95 Cr

Mar '26

Ram Mohan Lokhande

Whole Time Director

₹1.88 Cr

Mar '26

Girikrishna Maniar

Non Executive Independent Director

₹20.00 L

Mar '26

Hetal Gandhi

Non Executive Independent Director

₹20.00 L

Mar '26

Richa Goyal

Non Executive Independent Director

₹10.00 L

Mar '26

Anita Bandyopadhyay

Non Executive Independent Director

₹10.00 L

Mar '26

ACUTAAS Latest News

News

9 of 9 articles

COMPANY4 Sept 2026 · 14:29

Acutaas Chemicals inaugurates pilot plant in Surat

The pilot plant will support the R&D for new product trials and validations

EQUITY28 Aug 2026 · 13:07

Acutaas Chemicals informs about press release

COMPANY28 Aug 2026 · 11:51

Acutaas Chemicals’ arm inaugurates semiconductor chemicals manufacturing plant in South Korea

The plant was completed within 11 months of its groundbreaking on September 29, 2025

COMPANY24 Aug 2026 · 12:30

Acutaas Chemicals gets nod for Rs 212 crore capital expenditure plan

The project targets a production capacity of up to 81,000 metric tonnes per annum for new electronic grade chemicals

EQUITY18 Aug 2026 · 17:33

Acutaas Chemicals informs about updates

EQUITY20 Jul 2026 · 17:13

Acutaas Chemicals informs about conference call

EQUITY20 Jul 2026 · 13:28

Acutaas Chemicals submits board meeting intimation

EQUITY23 Jun 2026 · 11:59

Acutaas Chemicals informs about disclosures

EQUITY16 May 2026 · 15:43

Acutaas Chemicals informs about corporate presentation

ACUTAAS

₹3,365.00

+2.93%